P21: 340B Compliance Monitoring Utilizing Data Analytics  


Tim Krzeminski, Healthcare Compliance Director, PwC

Ryan Hayden, Partner, PricewaterhouseCoopers

  • Utilizing data analytics to monitor the 340B Drug Discount Program allows healthcare systems to ensure compliance with the 340B Program and maximizes cost-saving opportunities afforded by the 340B Program
  • KPIs allow for granular analysis of high risk area related to diversion, duplicate discounts, the GPO prohibition, and provide insights into missed cost- saving opportunities where split-billing software limitations and/or poor master data come into play
  • Reduce risk of fines and sanctions by regulators and protection against reputational damage; Improve risk management from automated continuous monitoring for 100% of transactions; Reduce number of FTEs used to maintain compliance with 340B program

Presentation & handouts

To save the video to your computer right-click the link above then choose SAVE TARGET AS (or SAVE LINK AS) then save the file.